The Top 5 Biosimilar Articles for the Week of October 26

October 30, 2020

Here are the top 5 biosimilar articles for the week of October 26, 2020.

ACR: UHC's New Co-pay Policy Is "Disastrous" for Patients
Part 2: Chad Pettit on “Head-to-Head” Biologics Competition
Mvasi, Kanjinti Add Heft to Amgen's Third-Quarter Sales
Advocacy Group Details Solutions for Sluggish Biosimilar Uptake

Biosimilars Poll: What are the characteristics of a healthy biologics marketplace?

October 28, 2020

Article

Opposing interests make it hard to define what elements are essential for a competitive marketplace.

Part 1: Chad Pettit on Amgen’s Assessment of the US Biosimilar Marketplace

October 27, 2020

Video

Chad Pettit, MBA, executive director of marketing and team leader for global biosimilar launches at Amgen, discussed Amgen’s recent report on the state of the US biosimilars marketplace.

Pfizer's Biosimilar Revenues Soar 80%

October 27, 2020

Tony Hagen

Article

The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story, although reference etanercept (Enbrel) sales have seen major erosion.

Alvotech Locks In $65 Million for Biosimilar Development

October 27, 2020

Tony Hagen

Article

With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.

Safety, Efficacy, and Savings Result From Study of Nonmedical Switching

October 26, 2020

Tony Hagen

Article

A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.

Legal Experts Weigh in on BPCIA Severability

October 26, 2020

Tony Hagen

Article

A trio of legal experts discuss Amy Coney Barrett's bid for a Supreme Court seat and how that might affect deliberations on the Affordable Care Act and the Biologics Price Competition and Innovation Act (BPCIA).

Samsung Bioepis Presents Real-World Switching Data for Renflexis

October 26, 2020

Tony Hagen

Article

A retrospective analysis of data from the US Veterans Affairs Healthcare System database provides positive switching data for infliximab products.

Not So Different: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary

October 25, 2020

Podcast

We spoke with Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs, for her take on requirements for comparative efficacy trails and whether they add meaningful data for the purposes of biosimilar acceptance.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Biocon Reports Biosimilars Revenue Growth

October 23, 2020

Tony Hagen

Article

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

x